Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000254
Chunk: 39

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 39
---
                                                                   
 an effort to address some of the pressing problems faced by modern healthcare, including healthcare costs, an aging population and developments 
 in medical technology that produce a stream of increasingly sophisticated treatments requiring more precise targeting.                          |

One additional key focus of Renovaro
Cube is its multi-modal, data analysis. Multi-modal data encompasses the whole aspect of data from a patient perspective, whether genomics,
imaging, phenotypic or even wearable data, which can be cross analyzed to produce data that could not be previously produced. Renovaro
Cube intends to use multi-modal data to bring new insights to the clinical and research teams trying to understand what to do next with
the patient.

Renovaro Cube’s Technology and Techniques

Renovaro Cube is dedicated to
the development of early cancer detection blood tests and expects to develop partnerships with third-party laboratories across the United
Kingdom, the Netherlands and the rest of Europe and will also expand to the United States. Renovaro Cube is focused on developing diagnostic
tests and test kits that would analyze samples derived from non-invasive liquid biopsy samples and intends to perform these tests from
Renovaro’s dedicated fully certified service laboratory and engage third-party laboratories to perform these tests for end-users.

<div align='center'>24</div>

For this purpose, Renovaro Cube
has developed an AI platform that aims to leverage expertise in both biological and computational sciences and to go beyond traditional
tumor signals by detecting the body’s early warning signs of cancer. Renovaro Cube’s goal is to provide accurate and reliable
tests that can aid in the early diagnosis and treatment of cancer. Renovaro Cube’s AI technology is created to detect a wide range
of biological signs to enhance the accuracy and sensitivity of early cancer detection and, thereby, enable earlier intervention and potentially
improved patient outcomes.

Renovaro Cube’s AI technology
aims to address three critical facets of medical needs within the domain of cancer diagnosis (as illustrated below):

| ● | type-specific cancer detection; |

| ● | pan-cancer detection; and |

| ● | patient stratification. |

Moreover, the versatility of Renovaro
Cube’s AI technology extends to encompass the realm of rare cancers, including cases such as cancer of unknown primary.

Leveraging DNA methylation data,
Renovaro Cube has identified and validated biomarker panels tailored for the detection of a wide range of cancers, including bladder,
breast, colon, prostate, thyroid, head and neck, liver, kidney and lung